NuVasive reports preliminary unaudited financial results for full year ended December 31, 2009

The Company reiterated 2010 revenue guidance of 30% – 35% growth, or $480 million to $500 million in revenues, and 2010 full year non-GAAP operating margin guidance of approximately 17%, expanding to approximately 20% in the fourth quarter of 2010.  Non-GAAP operating margin guidance excludes stock based compensation, amortization of intangibles, intellectual property litigation costs, and acquisition related charges.

NuVasive will not hold a conference call to discuss its preliminary unaudited full year 2009 financial results. The Company will announce complete financial and operating details of its fourth quarter and the full year ended December 31, 2009, and will give detailed guidance for 2010 after the market closes on February 25, 2010. The Company will hold a conference call the same day at 5:30 p.m. ET (2:30 p.m. PT).  

Alex Lukianov, Chairman and Chief Executive Officer, said, "We are pleased with the revenue growth and solid earnings leverage demonstrated in 2009, and we are very excited about the outlook for NuVasive in 2010. All of our products continue to gain market share as surgeon adoption expands. This week at the NuVasive Sales Meeting we look forward to recognizing our top performers and encouraging continued outstanding results in 2010."